Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Renal · FDA Approved

Desmopressin (DDAVP)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A synthetic analog of vasopressin (1-deamino-8-D-arginine vasopressin) with selective V2 receptor activity and minimal vasopressor activity. The deamination at position 1 and D-arginine at position 8 increase its antidiuretic action and duration while largely removing the blood pressure effects of native vasopressin.

It was approved by the FDA in 1978 for diabetes insipidus and bleeding disorders (PMID 31634354).

02 · Research summary & key findings

Used for central diabetes insipidus, bleeding disorders and childhood bedwetting (PMID 31634354) (PMID 40728007). Desmopressin releases stored von Willebrand factor and factor VIII, making it a non-transfusion option in mild to moderate hemophilia A and von Willebrand disease; a trial dose is usually given first because responses vary (PMID 40723839). A meta-analysis found that about 71% of patients with bleeding disorders responded, with response depending on disease subtype and baseline factor levels (PMID 39854691). In a population study of mostly older adults, desmopressin use was associated with a 13-fold higher rate of hyponatremia than a comparator drug (PMID 31634354).

03 · Regulatory status

Desmopressin (DDAVP) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Desmopressin (DDAVP) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Intranasal
  • Oral
  • Subcutaneous injection
  • Intravenous

References

  1. [1]Desmopressin and the risk of hyponatremia: A population-based cohort study PLoS Med, 2019. PMID 31634354
  2. [2]DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis Blood, 2025. PMID 39854691
  3. [3]A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero? Biomolecules, 2025. PMID 40723839
  4. [4]Desmopressin for nocturnal enuresis in children Cochrane Database Syst Rev, 2025. PMID 40728007

Primary literature

Related peptides in Renal

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.